Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00044746
NCT00044746CompletedPhase 4

An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients

Wyeth is now a wholly owned subsidiary of Pfizer0 sites314 target enrollmentStarted: October 1, 2000Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
314
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.

Study Design

Study Type
Interventional
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with diabetes mellitus
  • •Inpatient
  • •Have 1 or more infected ulcer(s) below the ankle

Exclusion Criteria

  • •Must not have gangrene or severely impaired arterial supply in your foot
  • •Must not have a bone infection in the area of your ulcer
  • •Must not have allergies to penicillins

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Completed
Phase 2
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised SubjectsInfluenza
NCT00979251Adamas Pharmaceuticals, Inc.2
Completed
Phase 3
Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)Psoriasis
NCT00254982Merck Sharp & Dohme LLC593
Recruiting
Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyMuscular Atrophy, Spinal
NCT05861999Hoffmann-La Roche28
Recruiting
Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyMuscular Atrophy, Spinal
NCT05861986Hoffmann-La Roche28
Completed
Phase 4
A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)Myelodysplastic Syndromes
NCT02145026Hoffmann-La Roche100